Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
First Claim
1. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
264 Citations
6 Claims
- 1. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient.
- 3. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient.
- 5. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of a pharmaceutically acceptable salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient.
Specification